Ypsomed Divests Pen Needle: Focuses on Insulin Pump Innovation

Ypsomed se desprende de Pen Needle: Se centra en la innovación en bombas de insulina

Jue, 28 mar 2024

Ypsomed traspasa el negocio de agujas para pluma y BGM a MTD, canalizando la inversión hacia la ampliación de la planta de Solothurn y la mejora de las soluciones para bombas de insulina.

Ypsomed, a notable player in the healthcare sector, has divested its pen needle and glucose monitoring systems (BGMs) segment to Medical Technology and Devices S.p.A. (MTD) según un comunicado de prensa.

This decision is aligned with Ypsomed’s vision to concentrate on advancing and commercialising its cutting-edge mylife Loop insulin pump solution. The transition to MTD, anticipated to finalise in summer 2024, is set to ensure a continuous supply of high-quality pen needles, catering to the global demand from insulin and hormone injectors.

In the interim, Ypsomed will continue manufacturing pen needles under a contract arrangement, facilitating a smooth transition by mid-2025. This business segment, now transitioning to MTD, recorded sales of over CHF 50 million in the fiscal year 2022/23, with a subsequent CHF 18 million in the first half of FY 2023/24.

MTD aims to enrich its portfolio with Ypsomed’s acclaimed click technology and its own 34G pen needle, envisioning expanded market reach and enhanced service to the diabetes community.

Ypsomed is set to channel over CHF 100 million into its Solothurn site over the next four years, boosting autoinjector production capabilities. This expansion will not only augment its manufacturing capacity but also introduce a new injection moulding tool shop, thereby creating numerous job opportunities.

Ypsomed assures its workforce of continued employment and is actively seeking avenues to accommodate all employees affected by the business transition within the group or through partner recruiting agencies.

Historias relacionadas

UBS Makes Big Repayments To The SNB For Emergency Liquidity

7 mayo 2024

UBS repays another CHF 9 billion in ELA to the Swiss National Bank, further reducing the emergency liquidity provided...

BNP Paribas (Suisse) Announces Job Cuts

3 mayo 2024

BNP Paribas (Suisse) to cut around 100 jobs at its Geneva location, focusing reductions in support and IT....

Geneva Will Not Remove Statues Of Colonialists & Racists

7 mayo 2024

Geneva opts for dialogue and historical context over removing statues or renaming places associated with racism and...

Swiss Train Derailment In Brig: Delays Ongoing

6 mayo 2024

Train service between Brig VS and Domodossola remains halted following a derailment caused by boulders on the tracks....

Bern Riots: 11 Policeman Injured & Arrests

6 mayo 2024

Unrest at Bern's Schützenmatte results in serious accusations by the regional police chief against rioters. ...

PSP Swiss Property: Strong Earnings

7 mayo 2024

PSP Swiss Property boosts 2024 earnings, with Q1 net profits up 42% to CHF 81 million. Revised EBITDA forecast now at...

Credit Suisse CEO To Step Down As UBS Merger Accelerates

6 mayo 2024

UBS plans to dissolve Credit Suisse's management in the coming weeks, with CEO Ulrich Körner leaving post-merger,...

Mantente en contacto

Cabe destacar

Cabe destacar

7 mayo 2024

UBS Job Cuts “Not Imminent”

Swiss Voters Lean Towards Approval of Health and Energy Initiatives, Poll Shows

Cabe destacar

24 abril 2024

Ypsomed se desprende de Pen Needle: Se centra en la innovación en bombas de insulina

Ypsomed se desprende de Pen Needle: Se centra en la innovación en bombas de insulina

Historias relacionadas

Mantente en contacto

Cabe destacar

UBS Job Cuts “Not Imminent”

Los votantes suizos se inclinan por la aprobación de iniciativas en materia de salud y energía, según un sondeo

Enlaces rápidos